Market Research Industry Reports

The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players


The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players


GBI Research’s latest report, The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players, provides an in-depth assessment of the current trends in the global mid-size pharma market, along with growth strategies being pursued by these companies.

The report contains an overview of mid-size pharma companies in terms of overall revenue, R&D spending, number of pipeline and marketed products, number of employees, location of headquarters, year-on-year revenue and R&D expenditure. It also includes profiles of the top mid-size companies with overall revenue forecasts, and sales forecasts for top marketed products and late-stage pipeline products up to 2023.

Pharmaceutical companies with annual revenue in 2016 of between $1 billion and $10 billion are considered to be mid-size companies in the report. The mid-size pharma market is growing rapidly. Most of these companies are focusing heavily on developing a portfolio of generic products covering a variety of therapy areas and geographies. They have been competing with large pharma by developing generic products of high value innovative biologics after their patent expiry.

Additionally, the top mid-size companies are involved in the end-to-end development of innovative products, although in these cases their focus is limited to specific therapy areas. A few mid-size companies diverge from the typical trends and are particularly focused on rare diseases. A wide range of strategies, such as mergers and acquisitions, in-house R&D, a shift towards high value generics and a focus on rare diseases, are being pursued by mid-size pharma companies to sustain and grow in the market.

This report provides key insights on the mid-size pharma industry, from data covering over 80 mid-size companies - both those focused exclusively on pharma, and those also involved in other divisions of healthcare, such as medical devices, in addition to pharma products.


- How can the mid-sized pharma segment be defined in general, and what is its role in the industry?
- Which mid-size pharma companies are on the leaders in terms of revenue, R&D expenditure, number of R&D products, marketed products and number of employees in 2016?
- What is the revenue forecast for the key mid-size companies in 2023?
- What are the key marketed products of the top mid-size pharma companies? What were the global sales figures in 2016 and what are the forecasts for 2023 for these products?
- Which therapy areas are the key mid-size companies are focusing on? What are the global sales forecasts of late-stage pipeline products that are set to enter the market during the forecast period?
- What was the year-on-year revenue growth and year-on-year R&D expenditure of key mid-size pharma companies between 2014 and 2016?
- What are the key strategies followed by mid-size pharma companies to improve their revenue and push towards joining the large pharma segment?
- What are the key challenges faced by mid-size pharma companies?

Reasons to buy

- Interpret the key players in the mid-size pharma segment through the analysis of companies, particularly based on R&D investments, year-on-year revenue and R&D expenditure, and pipeline and marketed products.
- Gain insights on how mid-size pharma companies have explored new technologies to shape their current portfolios and R&D pipelines.
- Understand the detailed profiling of top mid-size pharma companies based on their revenue in 2016. The profiling of the companies includes top-selling marketed products, major late-stage pipeline products expected to enter into the market in the near future and their forecasts, and key deals analysis.
- Recognize the various challenges faced by mid-size pharma companies.
- Understand the major growth strategies followed by mid-size pharma companies in recent years.

What is the Mid-Sized Pharma Segment and What is its Role in the Industry?
Why is Mid-size Pharma a Key Element of the Industry?
Mid-size Pharma Players with Revenue Forecasts
Comparative Analysis and Ranking - Based on
R&D Expenditure
Number of Pipeline Products
Number of Marketed Products
Number of Employees
Location of Headquarter
Year-on-Year Revenue
Year-on-Year R&D Expenditure
Key Points
Mid-size Pharma Companies - Growth Strategies related to Deals and Collaborations
Mergers and Acquisitions
Licensing Agreements and Partnerships
R&D Collaboration
Geographical Expansion
In-House Research and Development
Shift towards High-Value Generics from Low-Value Generics
Brand Building
Specialized Therapy Areas and Rare Diseases
Key Points
Top Mid-size Pharma Companies
Daiichi Sankyo
Valeant Pharmaceuticals
Regeneron Pharmaceuticals
Les Laboratories Servier
Sun Pharmaceutical
Endo International
Kyowa Hakko Kirin
Alexion Pharmaceuticals
Taisho Pharmaceutical
Top Marketed Products
Pipeline Overview
Late stage Products with Sales Forecast
Revenue Forecast
Deals by Value and Volume
Key Deals
Top Small Pharma Companies Likely to Enter the Mid-size Segment
Horizon Pharma
Intas Pharmaceuticals
Challenges Faced by Mid-size Pharma
List of Mid-size Pharma Companies

China’s Governance System: What the World Needs to Know About the Oriental Economic Superpower (2018 edition)

Since the reform and opening up to outside world policy was enforced in 1978, nearly 40 years of fast-paced economic growth has made China the worlds second largest economy and

USD 1500View Report

Global X Band Synthetic Aperture Radar Market Research Report 2018

X Band Synthetic Aperture Radar Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions,

USD 2850View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


  • PDF    USD 2995
  • Site Licence    USD 5990
  • Enterprise Wide Licence    USD 8985
$ 2995

Reports Details

Published Date : May 2018
No. of Pages :140
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :CBR Pharma Insights
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE


We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube